Achondroplasia awareness focuses on treatment access

World Achondroplasia Day, observed on October 25, highlights the medical and social challenges faced by individuals with this genetic condition. Achondroplasia is the most common form of disproportionate short stature, caused by a pathogenic variant in the FGFR3 gene which affects bone growth regulation.

While scientific advancements have led to new therapeutic possibilities, such as the drug vosoritide—which was approved in Argentina over a year ago—experts emphasize that access remains a significant barrier. Medical professionals and patient associations are calling for timely and equitable access to these treatments to prevent complications and improve quality of life.

Effective management requires early diagnosis, which can be suspected during pregnancy via ultrasound or identified at birth through clinical and radiological evaluations. Beyond medication, the medical community stresses the importance of early detection, interdisciplinary follow-up, and ensuring that therapeutic advances translate into comprehensive care for all affected children.